In March, the patent for semaglutide – the glucagon-like peptide-1 (GLP-1) drug sold worldwide as Ozempic or Wegovy for the treatment of diabetes and obesity – expired in India.
In March, the patent for semaglutide – the glucagon-like peptide-1 (GLP-1) drug sold worldwide as Ozempic or Wegovy for the treatment of diabetes and obesity – expired in India.